Werewolf Therapeutics Inc. has announced that its priorities for the coming year include a focus on the company’s Inducer T-cell engager platform, where preclinical studies have demonstrated robust silencing and reduction of off-tumor toxicity.
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers new clues for future therapies. Glioblastoma is one of the deadliest brain cancers, accounting for about half of all brain tumors, with a median survival rate of just 15 months. Despite surgery and chemotherapy, more than 1,250 clinical trials over the past 20 years have struggled to improve survival rates.
Alicorn Pharmaceutical Co. Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Liaoning Haisco Pharmaceutical Co. Ltd. has identified crystalline salts of known cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of cancer.
Farsight Medical Technology (Shanghai) Co. Ltd. has synthesized cyclosporin derivatives acting as peptidyl-prolyl cis-trans isomerase F, mitochondrial (PPIF; cyclophilin D) and/or peptidyl-prolyl cis-trans isomerase A (PPIA; cyclophilin A; CYPA) inhibitors reported to be useful for the treatment of asthma, cancer, multiorgan failure, viral infections, rheumatoid arthritis, renal disorders, neurological disorders and cardiovascular disorders, among others.
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has disclosed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Eilean Therapeutics LLC has announced it is advancing ZE74-0282 into first-in-human development, with the submission of an IND application and enrollment planned to begin in the first quarter of next year.
Circle Pharma Inc. has nominated CID-165, a first-in-class, orally bioavailable macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program.
Zelluna ASA has submitted a clinical trial application (CTA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1 (ZIMA-101), the company’s lead candidate. ZI-MA4-1 is a novel MAGE-A4-targeting T-cell receptor-natural killer (TCR-NK) therapy.
Although hormone receptor-positive (HR+) breast cancer accounts for over 70% of cases, 20%-30% of patients still experience relapse despite endocrine therapies such as tamoxifen. Recurrence is also observed in HER2+ breast cancer, even with HER2-targeted antibodies and antibody-drug conjugates (ADCs), the use of which can be limited by adverse effects such as interstitial lung disease.
RSS
